Related Experiment Video

Updated: Apr 5, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

RNF130 inhibits the proliferation, migration and invasion of osteosarcoma through DAB1 mediated suppression of the

Wenda Liu1, Liangyu Guo1, Zhengping Liu1

  • 1Department of Orthopaedics, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China.

Cellular Signalling
|April 4, 2026
PubMed
Abstract

Insights

Ring finger protein 130 (RNF130) acts as a tumor suppressor in osteosarcoma. Its decreased expression correlates with poor prognosis, and it inhibits cancer cell proliferation and metastasis by regulating the DAB1/PI3K/AKT/mTOR pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ring finger protein 130 (RNF130), also known as Goliath, is the mammalian homolog of Drosophila E3 ligase dGoliath.
  • Its precise role in osteosarcoma pathogenesis is not well understood, despite its investigation in other biological contexts.

Purpose of the Study:

  • To investigate the expression and functional role of RNF130 in osteosarcoma.
  • To elucidate the molecular mechanisms by which RNF130 influences osteosarcoma progression and patient survival.

Main Methods:

  • Analysis of RNF130 expression in osteosarcoma using TCGA dataset and correlation with patient survival.
  • In vivo phenotypic assays to assess the impact of RNF130 on osteosarcoma malignancy.
  • Transcriptome sequencing and co-immunoprecipitation to identify RNF130 regulatory pathways.
  • Xenograft tumor models in nude mice to validate RNF130's role in tumor growth.

Main Results:

  • RNF130 expression is significantly reduced in osteosarcoma tissues and linked to poorer overall survival.
  • Overexpression of RNF130 suppresses osteosarcoma cell proliferation, migration, and invasion, while RNF130 silencing promotes these malignant behaviors.
  • RNF130 functions as a tumor suppressor by regulating the DAB1/PI3K/AKT/mTOR signaling pathway through the ubiquitin-proteasome system.

Conclusions:

  • RNF130 exhibits tumor-suppressive activity in osteosarcoma, potentially serving as a prognostic biomarker.
  • RNF130 regulates osteosarcoma progression via the DAB1/PI3K/AKT/mTOR signaling pathway.
  • Further validation in larger, independent datasets is necessary to confirm the clinical prognostic value of RNF130.
Keywords:
DAB1OsteosarcomaPI3K/AKT/mTOR signaling pathwayRNF130Ubiquitin-proteasome degradation pathway

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.5K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K